Effect of clarithromycin pre-treatment on the pharmacokinetics of metoclopramide after their simultaneous oral intake

References

• Leone R, Magro L, Moretti U, et al. Identifying adverse drug reactions associated with drug-drug interactions. Drug Saf. 2010;33(8):667–675.
   Google Scholar
• Kuhlmann J, Mück W. Clinical-pharmacological strategies to assess drug interaction potential during drug development. Drug Saf. 2001;24(10):715–725.
   Google Scholar
• Kaukab I, Hussain Shah SN, Murtaza G. Single dose pharmacokinetics of metoclopramide oral tablets utilizing HPLC-UV method. Curr Pharm Anal. 2019;15(7):703–709.
   Google Scholar
• Chua EW, Harger SP, Kennedy MA. Metoclopramide-induced acute dystonic reactions may be associated with the CYP2D6 poor metaboliser status and pregnancy-related hormonal changes. Front Pharmacol. 2019;10:931.
   Google Scholar
• Choo KH, Manikam RAL, Yoong KPY, et al. Prophylactic metoclopramide use in trauma patients given tramadol: A randomised, double-blinded, placebo-controlled trial. Hong Kong J Emer Med. 2019;26(2):98–105.
   Google Scholar
• Tonini M, Candura SM, Messori E, et al. Therapeutic potential of drugs with mixed 5-HT4 agonist/5-HT3 antagonist action in the control of emesis. Pharmacol Res. 1995;31(5):257–260.
   Google Scholar
• Feldman M, Friedman LS, Brandt LJ. “Ch. 43: gastroesophageal reflux disease”. Sleisenger and Fordtran’s gastrointestinal and liver disease. 9th ed.Philadelphia: Saunders; 2010. ISBN 978-1-4160-6189-2.
   Google Scholar
• Desta Z, Wu GM, Morocho AM, et al. The gastroprokinetic and antiemetic drug metoclopramide is a substrate and inhibitor of cytochrome P450 2D6. Drug Metab Dispos. 2002;30(3):336–343.
   Google Scholar
• Yu J, Paine MJ, Maréchal JD, et al. In silico prediction of drug binding to CYP2D6: identification of a new metabolite of metoclopramide. Drug Metab Dispos. 2006;34(8):1386–1392.
   Google Scholar
• Doran A, Obach RS, Smith BJ, et al. The impact of P-glycoprotein on the disposition of drugs targeted for indications of the central nervous system: evaluation using the MDR1A/1B knockout mouse model. Drug Metab Dispos. 2005;33(1):165–174.
   Google Scholar
• Argikar UA, Gomez J, Ung D, et al. Identification of novel metoclopramide metabolites in humans: in vitro and in vivo studies. Drug Metab Dispos. 2010;38(8):1295–1307.
   Google Scholar
• Livezey MR, Briggs ED, Bolles AK, et al. Metoclopramide is metabolized by CYP2D6 and is a reversible inhibitor, but not inactivator, of CYP2D6. Xenobiotica. 2014;44(4):309–319.
   Google Scholar
• Westphal JF. Macrolide–induced clinically relevant drug interactions with cytochrome P‐450A (CYP) 3A4: an update focused on clarithromycin, azithromycin and dirithromycin. Br J Clin Pharmacol. 2000;50(4):285–295.
   Google Scholar
• Niemi M, Neuvonen PJ, Kivistö KT. The cytochrome P4503A4 inhibitor clarithromycin increases the plasma concentrations and effects of repaglinide. Clin Pharmacol Ther. 2001;70(1):58–65.
   Google Scholar
• Liukas A, Hagelberg NM, Kuusniemi K, et al. Inhibition of cytochrome P450 3A by clarithromycin uniformly affects the pharmacokinetics and pharmacodynamics of oxycodone in young and elderly volunteers. J Clin Psychopharmacol. 2011;31(3):302–308.
   Google Scholar
• Kaukab I, Shah S, Abrar MA, et al. Influence of rifampicin pre-treatment on the in vivo pharmacokinetics of metoclopramide in Pakistani healthy volunteers following concurrent oral administration. Curr Drug Metab. 2020. Advance online publication. DOI:10.2174/1389200221666200514132654
   Google Scholar
• Saari TI, Grönlund J, Hagelberg NM, et al. Effects of itraconazole on the pharmacokinetics and pharmacodynamics of intravenously and orally administered oxycodone. Eur J Clin Pharmacol. 2010;66(4):387–397.
   Google Scholar
• European Medicines Agency (EMA). Guideline on the investigation of drug interaction; 2010. [cited 2020 Feb 22]. Available from: www.ema.europa.eu
   Google Scholar
• Gorski JC, Jones DR, Haehner‐Daniels BD, et al. The contribution of intestinal and hepatic CYP3A to the interaction between midazolam and clarithromycin. Clin Pharmacol Ther. 1998;64(2):133–143.
   Google Scholar
• Pinto AG, Wang YH, Chalasani N, et al. Inhibition of human intestinal wall metabolism by macrolide antibiotics: effect of clarithromycin on cytochrome P450 3A4/5 activity and expression. Clin Pharmacol Ther. 2005;77(3):178–188.
   Google Scholar
• Mayhew BS, Jones DR, Hall SD. An in vitro model for predicting in vivo inhibition of cytochrome P450 3A4 by metabolic intermediate complex formation. Drug Metab Dispos. 2000;28(9):1031–1037.
   Google Scholar
• Kaukab I, Shah SNH, Kharaba Z, et al. Evaluation of pharmacokinetic interaction of cilostazol with metoclopramide after oral administration in human. Curr Drug Metab. 2019;20(11):924–928.
   Google Scholar
• Wrighton SA, Stevens JC. The human hepatic cytochromes P450 involved in drug metabolism. Crit Rev Toxicol. 1992;22(1):1–21.
   Google Scholar
• Abebe BT, Weiss M, Modess C, et al. Effects of the P‐glycoprotein inhibitor clarithromycin on the pharmacokinetics of intravenous and oral trospium chloride: a 4‐way crossover drug‐drug interaction study in healthy subjects. J Clin Pharmacol. 2019;59(10):1319–1330.
   Google Scholar
• Wacher VJ, Wu CY, Benet LZ. Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P‐glycoprotein: implications for drug delivery and activity in cancer chemotherapy. Mol Carcinog. 1995;13(3):129–134.
   Google Scholar
• Lilja JJ, Niemi M, Fredrikson H, et al. Effects of clarithromycin and grapefruit juice on the pharmacokinetics of glibenclamide. Br J Clin Pharmacol. 2007;63(6):732–740.
   Google Scholar